Heimberger Amy B, Abou-Ghazal Mohamed, Reina-Ortiz Chantal, Yang David S, Sun Wei, Qiao Wei, Hiraoka Nobuyoshi, Fuller Gregory N
Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Clin Cancer Res. 2008 Aug 15;14(16):5166-72. doi: 10.1158/1078-0432.CCR-08-0320.
The incidence of regulatory T cells (Treg) in intrinsic central nervous system malignancies is unknown. Immunotherapeutic approaches that inhibit the Treg population may be limited to a subset of patients with gliomas. Our hypothesis is that only the most malignant gliomas have a prominent glioma-infiltrating Treg population that contributes to the immunosuppressive biology and that the presence of Tregs is a negative prognostic variable.
We measured the incidence of Tregs in 135 glial tumors (including all pathologic types) in a glioma microarray using immunohistochemical analysis. Results were categorized according to the total number of Tregs within the tumors. Correlation of the presence of Tregs with prognosis was evaluated using univariate and multivariate analyses.
Tregs were not present in normal brain tissue and were very rarely found in low-grade gliomas and oligodendrogliomas. We observed significant differences in the prevalence of Tregs between astrocytic and oligodendroglial tumors, between tumors of different grades, and between different pathologic types of tumors. We identified Tregs most frequently in glioblastoma multiforme (GBM) but very rarely in low-grade astrocytomas. The presence of Tregs within GBMs did not alter the median survival in patients from whom the tumors were obtained.
Treg infiltration differed significantly in the tumors according to lineage, pathology, and grade. Tregs seemed to have the highest predilection for tumors of the astrocytic lineage and specifically in the high-grade gliomas, such as GBM. In both univariate and multivariate analysis, the presence of Tregs in GBMs seemed to be prognostically neutral.
调节性T细胞(Treg)在原发性中枢神经系统恶性肿瘤中的发生率尚不清楚。抑制Treg群体的免疫治疗方法可能仅适用于一部分胶质瘤患者。我们的假设是,只有最恶性的胶质瘤才有显著的胶质瘤浸润性Treg群体,这有助于免疫抑制生物学特性,并且Tregs的存在是一个负面的预后变量。
我们使用免疫组织化学分析在胶质瘤微阵列中测量了135例胶质肿瘤(包括所有病理类型)中Tregs的发生率。结果根据肿瘤内Tregs的总数进行分类。使用单变量和多变量分析评估Tregs的存在与预后的相关性。
正常脑组织中不存在Tregs,在低级别胶质瘤和少突胶质细胞瘤中也很少发现。我们观察到星形细胞瘤和少突胶质细胞瘤之间、不同级别的肿瘤之间以及不同病理类型的肿瘤之间Tregs的患病率存在显著差异。我们在多形性胶质母细胞瘤(GBM)中最频繁地鉴定出Tregs,但在低级别星形细胞瘤中很少见。GBM中Tregs的存在并未改变获取肿瘤的患者的中位生存期。
根据谱系、病理和级别,肿瘤中Treg浸润存在显著差异。Tregs似乎对星形细胞谱系的肿瘤,特别是高级别胶质瘤,如GBM,具有最高的偏好。在单变量和多变量分析中,GBM中Tregs的存在在预后方面似乎是中性的。